Quest Diagnostics Incorporated (DGX)

Market Cap	19.05B
Revenue (ttm)	10.16B
Net Income (ttm)	892.00M
Shares Out	110.98M
EPS (ttm)	7.91
PE Ratio	21.67
Forward PE	17.34
Dividend	$3.20 (1.87%)
Ex-Dividend Date	Apr 7, 2025

Volume	150,048
Open	172.54
Previous Close	172.84
Day's Range	170.05 - 172.70
52-Week Range	125.42 - 178.87
Beta	0.78
Analysts	Buy
Price Target	182.36 (+6.22%)
Earnings Date	Apr 22, 2025

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 56,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX
• Website: https://www.questdiagnostics.com

Financial Performance

In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $866.00 million, an increase of 1.88%.

Analyst Forecast

According to 14 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $182.36, which is an increase of 6.22% from the latest price.

Price Target

$182.36

(6.22% upside)

Analyst Consensus: Buy